|Bid||16.61 x 1200|
|Ask||41.54 x 1000|
|Day's Range||40.68 - 42.00|
|52 Week Range||33.33 - 87.24|
|Beta (5Y Monthly)||1.48|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 23, 2022 - Feb 28, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||56.43|
SAN CLEMENTE, Calif., May 20, 2022--Glaukos Corporation (NYSE: GKOS), an ophthalmic medical technology and pharmaceutical company focused on novel therapies for the treatment of glaucoma, corneal disorders and retinal diseases, today announced that its management is scheduled to virtually participate in the Piper Sandler Ophthalmology Symposium on Monday, May 23, 2022, at 2:00 p.m. ET.
Glaukos' (GKOS) soft Q1 results fail to impress investors.
Glaukos (GKOS) delivered earnings and revenue surprises of 26.92% and 11.35%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?